42 Results for "

β-arrestin pathway

" in MedChemExpress (MCE) Product Catalog:
Products (42)

42 Results for "β-arrestin pathway" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-P2106
CAS No.: 1886973-05-2
Research Areas:  

Cardiovascular Disease

Elabela(19-32) is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) activates the Gαi1 and β-arrestin-2 signaling pathways with EC50s of 8.6 nM and 166 nM. Elabela(19-32) induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart .
loading...
    loading...
6
6 Publications Verification
Cat. No.: HY-P2106A
Research Areas:  

Cardiovascular Disease

Elabela(19-32) TFA is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) TFA activates the Gαi1 and β-arrestin-2 signaling pathways with EC50s of 8.6 nM and 166 nM. Elabela(19-32) TFA induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-122197
CAS No.: 2579689-83-9
Purity:  99.88%
Research Areas:  

Cancer

ML339 is a selective CXCR6 antagonist with an IC50 of 140 nM. ML339 antagonizes β-arrestin recruitment and cAMP signaling pathway of human CXCR6 receptor induced by CXCL16, with IC50 of 0.3 μM and 1.4 μM, respectively. ML339 shows weaker activity against the recruitment of β-arrestin in mouse CXCR6 receptors, with an IC50 of 18 μM. ML339 has no inhibitory effect on CXCR5CXCR4CXCR6 and apelin receptor (APJ), with IC50 >79 μM. ML339 has the potential to promote the development of prostate cancer research .
loading...
    loading...
Cat. No.: HY-160734
CAS No.: 2685823-26-9
Synonyms: GSBR-1290
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Aleniglipron (GSBR-1290) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist, with an EC50 value of less than 0.1 nM in HDB cell lines in cAMP stimulation assays. Aleniglipron selectively activates the Gαs-cAMP signaling pathway of GLP-1R without β-arrestin recruitment. Aleniglipron induces insulin release, promotes glucose clearance, reduces food intake and decreases body weight. Aleniglipron is applicable to research related to type 2 diabetes and obesity .
loading...
    loading...
Cat. No.: HY-165428
CAS No.: 907206-98-8
Target:  

CXCR Arrestin

Research Areas:  

Inflammation/Immunology

SCH-900875 is an orally active, brain-penetrant and selective CXCR3 receptor inhibitor, which also shows high selectivity over CXCR1 and CXCR2 receptors. SCH-900875 binds to CXCR3, blocking the binding of ligands CXCL9, CXCL10, and CXCL11, inhibiting downstream G protein and β-arrestin signaling pathways to suppress inflammatory cell migration. SCH-900875 is promising for research of autoimmune diseases (rheumatoid arthritis, multiple sclerosis) and inflammatory disorders (psoriasis, inflammatory bowel disease) .
loading...
    loading...
Cat. No.: HY-136832
CAS No.: 110514-35-7
Noribogaine hydrochloride is an orally active, blood-brain barrier permeable SERT inhibitor (IC50=50-300 nM) and hERG channel blocker. Noribogaine hydrochloride enhances serotonergic transmission, activates the κ-opioid receptor (OPRK) G protein signaling pathway and inhibits β-arrestin recruitment. Meanwhile, Noribogaine hydrochloride blocks the μ-opioid receptor (OPRM) signaling pathway as well as ion channels associated with cardiac repolarization. Noribogaine hydrochloride induces neuritogenesis, upregulates GDNF mRNA expression, and modulates opioid tolerance. Noribogaine hydrochloride reduces alcohol-seeking behavior in experimental animals, and is widely used in studies related to depression, addiction, alcoholism, and cardiotoxicity .
loading...
    loading...
Cat. No.: HY-163671
CAS No.: 2767348-36-5
Target:  

GPR52 Arrestin

Research Areas:  

Neurological Disease

PW0729 is a selective GPR52 agonist. PW0729 activates G protein/cAMP signaling pathway, with bias toward this pathway over β-arrestin recruitment, and induces GPR52 desensitization. PW0729 can be used for the research of neuropsychiatric and neurological diseases .
loading...
    loading...
Cat. No.: HY-W077477
CAS No.: 313368-85-3
Target:  

5-HT Receptor Arrestin

Research Areas:  

Neurological Disease

IHCH-7113 is a 5-HT2AR agonist with EC50 values of 58.9 nM (Gq bioluminescence resonance energy transfer assay) and 44.7 nM (β-arrestin 2 bioluminescence resonance energy transfer assay). IHCH-7113 activates both Gαq-mediated signaling pathways and β-arrestin 2 recruitment pathways. IHCH-7113 is applicable for research related to depression .
loading...
    loading...
Cat. No.: HY-P2249
CAS No.: 2245073-05-4
Research Areas:  

Cardiovascular Disease

ELA-21 (human) is an apelin receptor agonist with a pKi of 8.52. ELA-21 (human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment with subnanomolar potencies. ELA-21 (human) is an agonist in G-protein-dependent and -independent pathways .
loading...
    loading...
Cat. No.: HY-110302
CAS No.: 2410327-94-3
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

6'-GNTI dihydrochloride, a κ-opioid receptor (KOR) agonist, displays bias toward the activation of G protein-mediated signaling over β-arrestin2 recruitment. 6'-GNTI 6'-GNTI dihydrochloride only activates the Akt pathway in striatal neurons .
loading...
    loading...
Cat. No.: HY-121800
CAS No.: 1355243-24-1
Research Areas:  

Neurological Disease

ML138 is a blood-brain barrier-permeable κ-opioid receptor (KOR) agonist, with an EC50 value of 0.87 μM and a human Ki value of 2.4 nM for human receptors; it exhibits high selectivity for KOR over μ, δ and other receptors. ML138 activates β-arrestin (beta-arrestin)-mediated signaling pathways, stimulates G protein coupling, and activates the downstream extracellular regulated protein kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAP kinase) signaling pathway. ML138 is applicable to research related to addictive behaviors .
loading...
    loading...
Cat. No.: HY-175231
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

ST171 is a bitopic 5-HT1AR agonist with an Ki of 0.41  nM. ST171 selectively activates Gi/o signaling pathway and inhibits 5-HT1AR-mediated cAMP accumulation without Gs activation and marginal β-arrestin recruitment. T171 reduces hypersensitivity in chronic neuropathic and inflammatory pain mice model. ST171 can be used for pain research .
loading...
    loading...
Cat. No.: HY-10486
CAS No.: 361444-66-8
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

JDTic is a blood-brain barrier-permeable κ-opioid receptor antagonist (Ki=0.02 nM) with favorable in vitro ADME properties. JDTic blocks agonist-mediated Gi and β-arrestin signaling pathways as well as analgesic effects by stabilizing the inactive conformation of hKOR and activating JNK. JDTic may also induce transient asymptomatic ventricular tachycardia. JDTic is widely applicable to studies related to depression, anxiety, stress-induced addictive behaviors, and nicotine withdrawal .
loading...
    loading...
Cat. No.: HY-P11237
CAS No.: 2869147-44-2
Synonyms: CT-388
Enicepatide (CT-388) is a cAMP signal-biased dual GLP-1R and GIPR agonist peptide, with an EC50 value of 0.087 nM for GLP-1R cAMP, and an EC50 value of 2.47 nM for GIPR cAMP. Enicepatide activates the cAMP signaling pathway, while recruiting only minimal amounts of β-arrestin-2 at both targets and reducing receptor internalization levels. Enicepatide improves glycemic control, reduces body weight, suppresses appetite, and ameliorates the pathological conditions of metabolic dysfunction-associated steatohepatitis. Enicepatide can be used in the research of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis .
loading...
    loading...
Cat. No.: HY-175001
Research Areas:  

Neurological Disease

D1/D5 Receptor agonist-1 is a highly brain-penetrant and orally active D1/D5 receptor agonist. D1/D5 Receptor agonist-1 maintains considerable efficacy in the cAMP pathway and in β-arrestin recruitment, with EC50s of 3.7 nM (D1R cAMP), 91 nM (D1R β-arrestin), 129 nM (D1R internalization) and a Ki of 111 nM (D1R binding affinity). D1/D5 Receptor agonist-1 inhibits β-arrestin signaling in a rat with L-DOPA (HY-N0304) induced dyskinesias. D1/D5 Receptor agonist-1 can be used for the study of Parkinson’s disease .
loading...
    loading...
Cat. No.: HY-138951
CAS No.: 1835734-92-3
AY77 is a calcium-biased PAR2 agonist. AY77 shows an EC50 of 0.17 and 2 nM in PAR2-mediated the activation in the Gq pathway and recruitment of β-arrestin-2, respectively. AY77 potently induces intracellular Ca 2+ release .
loading...
    loading...
Cat. No.: HY-173479
CAS No.: 3108380-54-4
Target:  

GLP Receptor

GLP-1R agonist 30 is a selective and orally active GLP-1R agonist with an EC50 of 0.048 nM. GLP-1R has excellent selectivity, with EC50 greater than 20 μM for GLP-2R, GIPR, and GCPR. GLP-1R agonist significantly increases cAMP-stimulating activity while markedly reducing hERG inhibitory activities. GLP-1R agonist has preferable absorption and excellent β-arrestin pathway selectivity. GLP-1R agonist effectively improves glucose tolerance and promoted insulin secretion in B-hGLP1R knock-in mice .
loading...
    loading...
Cat. No.: HY-172811
CAS No.: 2969158-02-7
Research Areas:  

Metabolic Disease

DA-302168S is an orally active and selective agonist targeting the GLP-1R, with EC50 value of 1.32 nM. DA-302168S reduces blood glucose levels and suppresses appetite, demonstrates minimal safety risks including low hERG channel inhibition and no significant off-target toxicity, and mitigates drug-drug interaction risk. DA-302168S can be used for the research of type 2 diabetes and obesity .
loading...
    loading...
Cat. No.: HY-141434
CAS No.: 74785-00-5
5-OxoETE methyl ester is the agonist for oxoeicosanoid receptor 1 (OXER1). 5-OxoETE methyl ester binds to OXER1, and activates downstream signaling pathways β-arrestin recruitment with an EC50 of 1.54 µM .
loading...
    loading...
Cat. No.: HY-W664041
CAS No.: 1609580-99-5
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

Noncatechol agonist-1 (19) is a Noncatechol agonist with full efficacy at both D1R-G protein and D1R-β-arrestin2 pathways, with pEC50 values of 8.41 for D1R-mediated cAMP production and 7.7 for β-arrestin2 recruitment, respectively .
loading...
    loading...